Tag: Novo Nordisk

Illustration showing pharmaceutical pricing mechanisms and cost-shifting through assistance programs
Health PolicyPolicy & Systems

Trump’s GLP-1 Drug Deal with Eli Lilly and Novo Nordisk Falls Short of Cost Control Goals

The Trump administration's voluntary pricing agreement with Eli Lilly and Novo Nordisk to control GLP-1 drug costs contains structural loopholes…

By
GMJ Policy Desk

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →